Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the ...
The deal which brings hundreds of thousands of agents under one roof also combines retail lender Guaranteed Rate's separate ...
Compass Inc. stock (NYSE: COMP) has been experiencing significant pressure, having declined over 15% within the last week, while the S&P 500 only fell by 0.6%. The catalyst for this decline: Compass’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback